CSL (ASX:CSL) is back in focus after cutting its FY26 revenue guidance, flagging about US$5b in additional Vifor related impairments and progressing a CEO transition along with broader commercial restructuring.

See our latest analysis for CSL.

CSL’s share price rose 5.75% in the last session to A$97.91 and is up 1.35% over seven days. However, the 30 day share price return is down 18.33% and the one year total shareholder return is down 58.53%, which points to fading longer term momentum despite the recent bounce driven by guidance cuts, impairments, CEO transition news and insider buying.

If CSL’s move has you reassessing healthcare exposure, this could be a good moment to review other biotech and pharma plays using a dedicated screener for 9 healthcare AI stocks

With CSL trading at A$97.91, sitting well below many analysts’ targets and recent years’ levels, the key question is whether the impairments and guidance reset are already reflected in the price, or whether the stock still offers a genuine buying opportunity that markets are not fully pricing in.

Most Popular Narrative: 36.8% Undervalued

According to the most followed CSL narrative from user Kouj, the fair value sits at A$155 versus the last close at A$97.91, with the gap driven by a view that current earnings are temporarily distorted rather than structurally impaired.

CSL is cheap by almost every measure. The market is currently paying 18.7x earnings for a business that has historically traded at 28 to 30x and sits in a sector where its peers average 36x. That gap exists because FY2026 earnings are distorted by one-off restructuring charges not because the underlying business has deteriorated.

Read the complete narrative.

Want to see what Kouj assumes happens once those one off charges roll off, margins reset, and earnings growth reverts to a more normal pattern? The key question is how fast profits rebuild under those conditions and what kind of multiple the market might be willing to pay for that earnings profile.

Result: Fair Value of A$155 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative can break if Vifor underperforms expectations or if the planned cost savings and broader restructuring fail to translate into stronger, cleaner earnings.

Find out about the key risks to this CSL narrative.

Next Steps

If this mix of concern and optimism feels familiar, do not wait on the sidelines. Review the full picture yourself by checking the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you are reassessing your watchlist after CSL, now is the time to broaden your view and line up a few fresh candidates before the next move.

• Target resilience with companies that emphasise financial strength by using the solid balance sheet and fundamentals stocks screener (19 results) to find stocks backed by healthier balance sheets and fundamentals.
• Hunt for potential value opportunities by checking the 6 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Spot companies the market may be overlooking by scanning the screener containing 12 high quality undiscovered gems and get ahead of ideas before they become crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.